Abstract

The purpose of this paper was to unravel the clinical effect analysis of different doses of creatine phosphate sodium (CPS) combined with immunoglobulin in the treatment of pediatric viral myocarditis (VMC). One hundred and twenty children with VMC were recruited and randomized into three groups (40 patients each). Group I received 1.0 g of CPS dissolved in 100 mL of 5% glucose injection intravenously 1 time/day; group II received 1.25 g of CPS dissolved in 125 mL of 5% glucose injection intravenously 1 time/day; group III received 1.5 g of CPS dissolved in 150 mL of 5% glucose injection intravenously 1 time/day; then all three groups were treated with combined use of immunoglobulin (300–400 mg/day) intravenously once a day; and all three groups were treated for 14 days. The clinical efficacy, cardiac function, serum inflammatory factor levels, immune function, and the occurrence of drug toxicity and adverse effects of the children in the three groups were compared after 14 days of treatment. All three groups achieved better therapeutic effects after treatment, in which the effective rate of the Group II and Group III was notably higher versus the Group I. Lower levels of cTnI, CK-MB, LDH, AST, IL-18, IL-6, IFN-γ, and LVEDD and higher CD3⁺, CD4⁺, and CD4⁺/CD8⁺, FS, and LVEF values were noted in the Group II and Group III versus the Group I, and the results were more pronounced in the high-dose group. The liver and kidney functions of the children in the three groups before and after treatment did not show any significant changes and the incidence of adverse reactions during the treatment period was low in all three groups. Children with VMC can be treated with high-dose CPS in combination with immunoglobulin, which can improve their cardiac function and immune function and reduce the inflammatory response with good overall therapeutic efficacy and fewer adverse effects.

中文翻译：

---

不同剂量磷酸肌酸钠联合免疫球蛋白治疗小儿病毒性心肌炎的临床效果分析

摘要

【摘要】：目的探讨不同剂量磷酸肌酸钠(CPS)联合免疫球蛋白治疗小儿病毒性心肌炎(VMC)的临床效果分析。招募了 120 名 VMC 儿童并随机分为三组（每组 40 名患者）。 I组将CPS 1.0 g溶于100 mL 5%葡萄糖注射液中静脉滴注，1次/d； II组将CPS 1.25 g溶于125 mL 5%葡萄糖注射液中静脉滴注，1次/d。 III组将CPS 1.5 g溶于150 mL 5%葡萄糖注射液中静脉滴注，1次/d。然后三组均联合使用免疫球蛋白（300-400mg/天）静脉注射，每天一次；三组均治疗14天。治疗14天后比较三组患儿的临床疗效、心功能、血清炎症因子水平、免疫功能以及药物毒性及不良反应的发生情况。三组治疗后均取得较好的治疗效果，其中II组和III组有效率明显高于I组。 cTnI、CK-MB、LDH、AST、IL-18、IL-6水平较低与第 I 组相比，第 II 组和第 III 组的 、IFN-γ 和 LVEDD 以及更高的 CD3 ⁺、CD4 ⁺和 CD4 ⁺ /CD8 ⁺、FS 和 LVEF 值在高组中更为明显。 -剂量组。三组患儿治疗前后肝肾功能均无明显变化，治疗期间不良反应发生率均较低。 VMC患儿可采用大剂量CPS联合免疫球蛋白治疗，可改善其心功能和免疫功能，减轻炎症反应，总体疗效好，不良反应少。